Arca
Skip to content
Tools
Tools

SLC22A12: Solute carrier family 22 member 12

Electroneutral antiporter that translocates urate across the apical membrane of proximal tubular cells in exchange for monovalent organic or inorganic anions.

  • Drugs that act on it: 8
  • Approved: 3
  • In phases 1 to 3: 5
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on SLC22A12, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 8

Approved3

  • Benzbromarone
  • Lesinurad
  • Sulfinpyrazone

Phase 32

  • Dotinurad
  • SHR-4640

Phase 23

  • Arhalofenate
  • Pratosartan
  • Verinurad

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Ardea Biosciences, Inc.113%
    • Crystalys Therapeutics113%
    • InventisBio Co., Ltd113%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Solute carrier family 22 member 12 inhibitor.
    BenzbromaroneWithdrawnApprovedInventisBio Co., LtdSmall moleculeInhibitor1
    LesinuradBoxed warningApprovedIronwood PharmaceuticalsSmall moleculeInhibitor0
    SulfinpyrazoneApprovedNovartis PharmaceuticalsSmall moleculeInhibitor0
    DotinuradPhase 3Crystalys TherapeuticsSmall moleculeInhibitor5
    SHR-4640Phase 3Jiangsu Hengrui MedicineSmall moleculeInhibitor1
    ArhalofenatePhase 2Gilead SciencesSmall moleculeInhibitor0
    PratosartanPhase 2—Small moleculeInhibitor0
    VerinuradPhase 2Ardea Biosciences, Inc.Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
    The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution TimeDotinuradPhase 4Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical UniversityJun 22, 2026
    A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout ParticipantsDotinuradPhase 2RecruitingCrystalys TherapeuticsApr 16, 2026
    The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaSHR-4640Phase 2RecruitingJiangsu HengRui Medicine Co., Ltd.Jan 23, 2026
    A Study of Dotinurad Versus Allopurinol in Participants With GoutDotinuradPhase 3RecruitingCrystalys TherapeuticsJul 28, 2025
    A Study of Dotinurad Versus Allopurinol in Tophaceous GoutDotinuradPhase 3RecruitingCrystalys TherapeuticsJul 28, 2025
    Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release TabletsBenzbromaronePhase 4RecruitingHuashan HospitalMay 13, 2025
    Effect of Dotinurad in Hyperuricemia With HypertensionDotinuradPhase 4RecruitingSaga UniversityFeb 19, 2025

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Hereditary renal hypouricemia0.66
    • Hypouricemia, renal0.47
    • Obesity disorder0.44
    • Acquired metabolic disease0.37
    • Overnutrition0.35
    • Obstructive sleep apnea syndrome0.28
    • Hypertensive disorder0.27
    • Placenta praevia0.22
    • Type 2 diabetes mellitus0.22
    • Hereditary disease0.19

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL6120, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q96S37, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.